The Registry of Toxic Effects of Chemical Substances

Acetamide, N - fluoren - 2 - yl -

RTECS #: AB9450000

CAS #: 53-96-3


UPDATE: May 2005 MW: 223.29 MF: C15H13NO


NOTE:

TABLE OF CONTENTS:
  1. SYNONYMS:
  2. MUTATION DATA:
  3. REPRODUCTIVE EFFECTS DATA:
  4. TUMORIGENIC DATA:
  5. ACUTE TOXICITY DATA:
  6. OTHER MULTIPLE DOSE DATA:
  7. REVIEWS:
  8. STANDARDS AND REGULATIONS:
  9. NIOSH DOCUMENTATION AND SURVEILLANCE:
  10. STATUS IN FEDERAL AGENCIES:
  11. REFERENCES:

SYNONYMS:

  1. 2 - (Acetylamino) fluorene
  2. 2 - AAF
  3. 2 - Acetamidofluorene
  4. 2 - Acetaminofluorene
  5. 2 - Acetylamino - fluoren (German)
  6. 2 - Acetylaminofluorene
  7. 2 - Acetylaminofluorene (OSHA)
  8. 2 - FAA
  9. 2 - Fluorenylacetamide
  10. 2AAF
  11. AAF
  1. Acetamide, N - 9H - fluoren - 2 - yl - (9CI)
  2. Acetoaminofluorene
  3. Acetylaminofluorene
  4. Azetylaminofluoren (German)
  5. FAA
  6. N - 2 - Fluorenylacetamide
  7. N - 9H - Fluoren - 2 - ylacetamide
  8. N - Acetyl - 2 - aminofluorene
  9. N - Fluoren - 2 - ylacetamide
  10. RCRA waste number U005


SKIN AND EYE IRRITATION DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
N/R
N/R N/R N/R


MUTATION DATA AND REFERENCES:

SYSTEM TEST ROUTE/
ORGANISM/
TISSUE
DOSE REFERENCE
body fluid assay mouse
Salmonella typhimurium
20 mg/kg MUREAV 117,79,1983
body fluid assay rat
Salmonella typhimurium
1,600 µg/kg PNASA6 71,737,1974
body fluid assay rat
ovary
53 mg/kg MUREAV 143,263,1985
cytogenetic analysis hamster lung 10 mg/L ATSUDG 4,41,1980
cytogenetic analysis oral
rat
50 mg/kg MUREAV 251,59,1991
cytogenetic analysis rat liver 10 mg/L MUREAV 64,329,1979
DNA adduct wild bird lymphocyte 700 pmol/plate CNREA8 37,3756,1977
DNA adduct Escherichia coli 5 µmol/L MUREAV 89,95,1981
DNA adduct human HeLa cell 5 µmol/L MUREAV 89,95,1981
DNA adduct human other cell types 1,200 nmol/L PAACA3 24,63,1983
DNA adduct human fibroblast 50 µmol/L/2 hour MUREAV 484,3,2001
DNA adduct mouse liver 60 µmol/L JJIND8 62,947,1979
DNA adduct mouse Ascites tumor 5 µmol/L MUREAV 89,95,1981
DNA adduct intraperitoneal
rat
18 µmol/kg CBINA8 48,15,1984
DNA adduct oral
rat
70 mg/kg CRNGDP 15,857,1994
DNA adduct intraperitoneal
rat
50 mg/kg MUTAEX 17,45,2002
DNA damage Bacillus subtilis 1 mg/disc PMRSDJ 1,175,1981
DNA damage hamster lung 300 µmol/L/2 hour BBRCA9 72,732,1976
DNA damage hamster lung 0.1 mmol/L/24 hour MUREAV 521,57,2002
DNA damage human other cell types 50 µmol/L MUREAV 468,277,2000
DNA damage human fibroblast 1 mmol/L ENMUDM 7,267,1985
DNA damage human liver 150 µmol/L/12 hour MUREAV 519,163,2002
DNA damage intraperitoneal
mouse
300 mg/kg MUREAV 493,39,2001
DNA damage oral
mouse
600 mg/kg MUREAV 493,39,2001
DNA damage oral
other insects
0.25 µmol/tube MUREAV 480-481,139,2001
DNA damage rat liver 3 µmol/L SinJF# 26OCT1982
DNA damage rat liver 2,000 ppm ENMUDM 4,667,1982
DNA damage rat liver 50 µg/L ENMUDM 6,427,1984
DNA damage rat liver 100 µmol/L/12 hour MUREAV 519,163,2002
DNA inhibition oral
mouse
160 mg/kg CBINA8 5,153,1972
DNA inhibition intraperitoneal
mouse
200 mg/kg MUREAV 46,305,1977
DNA inhibition rat liver 100 nmol/L CNREA8 45,337,1985
DNA inhibition oral
rat
420 mg/kg/6 week CNREA8 33,397,1973
DNA repair oral
Drosophila melanogaster
500 mg/L MUREAV 290,175,1993
DNA repair Escherichia coli 10 mg/L JJIND8 62,873,1979
DNA repair hamster ovary 6.25 µmol/L/18 hour MUREAV 564,139,2004
DNA repair rat liver 1 µmol/L JJCREP 79,204,1988
DNA repair Schizosaccharomyces pombe 2,800 nmol/L CNJGA8 24,771,1982
unscheduled DNA synthesis hamster liver 10 nmol/L ENMUDM 6,1,1984
unscheduled DNA synthesis human fibroblast 100 µmol/L/5 hour IJCNAW 16,284,1975
unscheduled DNA synthesis human HeLa cell 10 µmol/L CNREA8 38,2621,1978
unscheduled DNA synthesis human liver 1 µmol/L BANRDU 13,101,1982
unscheduled DNA synthesis human liver 0.2 µmol/L/24 hour FCTOD7 39,999,2001
unscheduled DNA synthesis mouse liver 10 µmol/L ENMUDM 5,1,1983
unscheduled DNA synthesis rat liver 2 µg/L MUREAV 190,159,1987
unscheduled DNA synthesis oral
rat
5 mg/kg MUREAV 150,383,1985
unscheduled DNA synthesis rat other cell types 3,200 µmol/L SHKKAN 22,300,1980
unscheduled DNA synthesis rat sperm 100 µmol/L ENMUDM 6,273,1984
unscheduled DNA synthesis intraperitoneal
rat
10 mg/kg CALEDQ 22,211,1984
unscheduled DNA synthesis rat liver 0.1 mg/L/18 hour MUREAV 472,75,2000
unscheduled DNA synthesis rabbit other cell types 10 µmol/L CRNGDP 8,401,1987
unscheduled DNA synthesis Salmonella typhimurium 1 µg ECEBDI 50,271,1982
host-mediated assay mouse
Salmonella typhimurium
495 mg/kg JJIND8 62,911,1979
host-mediated assay rat
Salmonella typhimurium
90 mg/kg/5 day AJCNAC 30,1921,1977
mutation in microorganisms Escherichia coli 100 µg/plate (+enzymatic activation step) PMRSDJ 1,387,1981
mutation in microorganisms Escherichia coli 64 mg/L/16 hour MUREAV 493,127,2001
mutation in microorganisms hamster ovary 20 mg/L (+enzymatic activation step) MUREAV 112,329,1983
mutation in microorganisms mouse lymphocyte 40 mg/L (+enzymatic activation step) ENMUDM 7(Suppl 3),10,1985
mutation in microorganisms mouse lymphocyte 12,300 µg/L (+enzymatic activation step) EMMUEG 12(Suppl 13),37,1988
mutation in microorganisms other microorganisms 200 µg/plate (+enzymatic activation step) CBINA8 22,297,1978
mutation in microorganisms Salmonella typhimurium 300 ng/plate (-enzymatic activation step) ENMUDM 6(Suppl 2),1,1984
mutation in microorganisms Salmonella typhimurium 1 nmol/plate/20 minute EMMUEG 38,268,2001
mutation in microorganisms Salmonella typhimurium 15 µg/plate (+enzymatic activation step) MUREAV 498,107,2001
mutation in microorganisms Salmonella typhimurium 0.5 mg/plate/45 minute (+enzymatic activation step) TCMUD8 22,285,2002
mutation in microorganisms Salmonella typhimurium mammary gland 50 µg/plate/24 hour (+enzymatic activation step) EMMUEG 41,55,2002
mutation in microorganisms Salmonella typhimurium 4 mg/L/72 hour (+enzymatic activation step) MUREAV 558,181,2004
mutation in microorganisms Salmonella typhimurium 100 µg/plate/72 hour MUREAV 558,145,2004
mutation in microorganisms Salmonella typhimurium 10 µmol/L/48 hour MUREAV 562,151,2004
mutation in microorganisms Saccharomyes cerevisiae 100 mg/L (+enzymatic activation step) CPBTAL 33,1576,1985
mutation in microorganisms Schizosaccharomyces pombe 100 µg/L (+/-enzymatic activation step) PMRSDJ 1,424,1981
micronucleus test intraperitoneal
hamster
2 gm/kg MUREAV 43,255,1977
micronucleus test hamster embryo 1 µmol/L MUREAV 203,397,1988
micronucleus test hamster lung 100 mg/L MUREAV 468,137,2000
micronucleus test human liver 0.17 µmol/L/20 hour MUREAV 536,79,2003
micronucleus test intraperitoneal
mouse
2 mg/kg PMRSDJ 1,686,1981
micronucleus test oral
mouse
75 mg/kg MUREAV 223,361,1989
micronucleus test mouse mammary gland 28 mg/L/3 hour (+enzymatic activation step) MUREAV 540,153,2003
micronucleus test oral
rat
50 mg/kg MUREAV 251,59,1991
gene conversion and mitotic recombination Saccharomyes cerevisiae 1 gm/L PMRSDJ 1,434,1981
mutation in mammalian somatic cells human lymphocyte 25 µmol/L ENMUDM 4,304,1982
mutation in mammalian somatic cells mouse lymphocyte 15 mg/L MUREAV 125,291,1984
mutation in mammalian somatic cells rat liver 1 µmol/L MUREAV 130,53,1984
mutation in mammalian somatic cells oral
rat
360 mg/kg/30 day- continuous CALEDQ 143,249,1999
morphological transform intraperitoneal
hamster
750 mg/kg ARPAAQ 95,380,1973
morphological transform hamster kidney 80 µg/L BJCAAI 37,873,1978
morphological transform hamster embryo 12,500 µg/L JJIND8 67,1303,1981
morphological transform mouse mammary gland 1 µg/L CNREA8 39,1784,1979
morphological transform intraperitoneal
rat
200 mg/kg CRNGDP 10,435,1989
morphological transform oral
rat
480 mg/kg/8 week- intermittent CRNGDP 5,171,1984
morphological transform rat embryo 100 µg/L JJIND8 67,1303,1981
morphological transform rat liver 100 µmol/L CNREA8 43,5087,1983
other mutation test systems Escherichia coli 100 µmol/L MUREAV 203,81,1988
other mutation test systems oral
mouse
160 mg/kg CBINA8 5,153,1972
other mutation test systems oral
rat
72 mg/kg/3 day- continuous EXMPA6 31,333,1979
other mutation test systems oral
rat
420 mg/kg/6 week CNREA8 33,397,1973
other mutation test systems Salmonella typhimurium 50 mg/L MUREAV 192,239,1987
phage inhibition capacity Escherichia coli 200 mg/L PMRSDJ 1,224,1981
sister chromatid exchange parenteral
chicken
3,125 ng/kg ENMUDM 2,435,1980
sister chromatid exchange intraperitoneal
hamster
50 mg/kg MUREAV 113,33,1983
sister chromatid exchange hamster ovary 100 µmol/L/150 minute MUREAV 58,103,1978
sister chromatid exchange oral
hamster
50 mg/kg MUREAV 113,33,1983
sister chromatid exchange hamster liver 6 mg/L MUREAV 207,69,1988
sister chromatid exchange human lymphocyte 4,400 µg/L CNREA8 40,4775,1980
sister chromatid exchange intraperitoneal
mouse
20 mg/kg MUREAV 157,181,1985
sister chromatid exchange intraperitoneal
rat
100 mg/kg MUREAV 91,363,1981
sister chromatid exchange skin
rat
100 mg/kg MUREAV 91,363,1981
sister chromatid exchange rat liver 4,500 µmol/L MUREAV 93,409,1982
sister chromatid exchange rat other cell types 400 µmol/L MUREAV 93,409,1982
sister chromatid exchange oral
rat
25 mg/kg MUREAV 251,59,1991
sister chromatid exchange intraperitoneal
rabbit
3 mg/kg MUREAV 58,321,1978
sex chromosome loss and nondisjunction hamster liver 100 mg/L PMRSDJ 5,397,1985
sex chromosome loss and nondisjunction oral
rat
50 mg/kg CRNGDP 17,1051,1996
sex chromosome loss and nondisjunction parenteral
silkworm
500 µg KIKNAJ (28),71,1977
sex chromosome loss and nondisjunction Saccharomyes cerevisiae 50 mg/L PMRSDJ 1,468,1981
specific locus test parenteral
Drosophila melanogaster
20 mmol/L IJCNAW 9,284,1972
specific locus test oral
Drosophila melanogaster
1 mmol/L/24 hour MUREAV 514,87,2002
specific locus test hamster ovary 5 mg/L/9 day EMMUEG 16,260,1990
specific locus test hamster lung 1 µmol/L/24 hour MUREAV 521,57,2002
specific locus test intraperitoneal
mouse
223 mg/kg MUREAV 117,201,1983
specific locus test oral
other insects
1,000 ppm MUREAV 268,155,1992
specific locus test oral
rat
6 mg/kg/4 day- continuous CALEDQ 135,215,1999
sperm morphology intraperitoneal
mouse
625 mg/kg/5 day- continuous MUREAV 124,235,1983


REPRODUCTIVE EFFECTS DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
intraperitoneal
mouse
lowest published toxic dose: 100 mg/kg (10 day pregnant) Reproductive: Effects on embryo or fetus: Fetotoxicity (except death, e.g., stunted fetus)

Reproductive: Specific developmental abnormalities: Musculoskeletal system
KAIZAN 37,239,1962
intraperitoneal
mouse
lowest published toxic dose: 100 mg/kg (8 day pregnant) Reproductive: Effects on fertility: Post- implantation mortality (e.g., dead and/or resorbed implants per total number of implants) KAIZAN 37,239,1962
intraperitoneal
mouse
lowest published toxic dose: 625 mg/kg (5 day male) Reproductive: Paternal effects: Spermatogenesis (including genetic material, sperm morphology, motility, and count) MUREAV 124,235,1983
intraperitoneal
mouse
lowest published toxic dose: 2,500 mg/kg (5 day male) Reproductive: Paternal effects: Testes, epididymis, sperm duct MUREAV 124,235,1983
oral
rat
lowest published toxic dose: 300 mg/kg (9 day pregnant) Reproductive: Specific developmental abnormalities: Central nervous system IARCCD 4,112,1973


TUMORIGENIC DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
implant
mouse
lowest published toxic dose: 96 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors
GMCRDC 17,383,1975
implant
rat
lowest published toxic dose: 22 mg/kg Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Skin and Appendages: Tumors

Tumorigenic: Tumors at site of application
CNREA8 33,2489,1973
intraperitoneal
mouse
lowest published toxic dose: 60 mg/kg/2 week- intermittent Tumorigenic: Neoplastic by RTECS criteria

Lung, Thorax, or Respiration: Tumors
TXAPA9 82,19,1986
intraperitoneal
rat
lowest published toxic dose: 192 mg/kg/4 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Skin and Appendages: Tumors
CNREA8 32,1554,1972
intraperitoneal
rabbit
lowest published toxic dose: 3,600 mg/kg/40 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors
CNREA8 27,838,1967
intratracheal
hamster
lowest published toxic dose: 8,800 mg/kg/73 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors
JNCIAM 50,503,1973
multiple
hamster
lowest published toxic dose: 3,370 mg/kg/37 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors
INURAQ 14,206,1976
oral
cat
lowest published toxic dose: 11 gm/kg/69 week- continuous Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors
CNREA8 11,280,1951
oral
chicken
lowest published toxic dose: 2,800 mg/kg/13 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Tumors

Liver: Tumors
BJCAAI 9,163,1955
oral
dog
lowest published toxic dose: 2,625 mg/kg/25 week- continuous Tumorigenic: Neoplastic by RTECS criteria

Liver: Tumors
CNREA8 10,266,1950
oral
hamster
lowest published toxic dose: 9,240 mg/kg/44 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors
GANNA2 59,239,1968
oral
mouse
lowest published toxic dose: 2,738 mg/kg/2.5 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Kidney, Ureter, and Bladder: Bladder tumors
JTEHD6 33,327,1991
oral
mouse
lowest published toxic dose: 7,840 mg/kg/49 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Kidney, Ureter, and Bladder: Bladder tumors
EJCAAH 5,41,1969
oral
mouse
toxic dose : 13 gm/kg/53 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Kidney, Ureter, and Bladder: Bladder tumors
JCPCBR 19,591,1979
oral
mouse
toxic dose : 13,140 mg/kg/1 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Skin and Appendages: Tumors
TXAPA9 41,535,1977
oral
mouse
lowest published toxic dose: 792.8 mg/kg/12 week- continuous Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Colon tumors

Tumorigenic: Increased incidence of tumors in susceptible strains
MUREAV 477,125,2001
oral
rat
lowest published toxic dose: 4,368 mg/kg/2 year- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Kidney, Ureter, and Bladder: Bladder tumors
JJCREP 84,237,1993
oral
rat
lowest published toxic dose: 672 mg/kg/8 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors
TXAPA9 74,63,1984
oral
rat
toxic dose : 2,100 mg/kg/25 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors
CALEDQ 19,55,1983
oral
rat
toxic dose : 1,220 mg/kg/19 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Skin and Appendages: Tumors
CNREA8 22,1002,1962
oral
rat
toxic dose : 2,100 mg/kg/30 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Skin and Appendages: Tumors
TXAPA9 5,526,1963
oral
rat
toxic dose : 2,610 mg/kg/23 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Skin and Appendages: Tumors
JNCIAM 10,1201,1950
oral
rat
toxic dose : 1,344 mg/kg/16 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Liver: Hepatitis, fibrous (cirrhosis, post- necrotic scarring)
TXAPA9 19,687,1971
oral
rat
toxic dose : 2,940 mg/kg/35 week- continuous Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Nutritional and Gross Metabolic: Weight loss or decreased weight gain
TXAPA9 19,687,1971
oral
rat
lowest published toxic dose: 1.008 mg/kg/6 week- continuous Tumorigenic: Neoplastic by RTECS criteria

Blood: Tumors

Tumorigenic: Facilitates action of known carcinogens
CALEDQ 154,121,2000
oral
rat
lowest published toxic dose: 60 mg/kg/3 day- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors

Tumorigenic: Facilitates action of known carcinogens
TXCYAC 171,161,2002
oral
rabbit
lowest published toxic dose: 6,500 mg/kg/65 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors

Kidney, Ureter, and Bladder: Kidney tumors
PAMIAD 32,177,1968
oral
rabbit
toxic dose : 14 gm/kg/56 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Kidney, Ureter, and Bladder: Bladder tumors

Reproductive: Tumorigenic effects: Ovarian tumors
CNREA8 27,838,1967
parenteral
chicken
lowest published toxic dose: 3,430 mg/kg/3 year Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Lung, Thorax, or Respiration: Tumors

Kidney, Ureter, and Bladder: Kidney tumors
BJCAAI 8,147,1954
parenteral
rat
lowest published toxic dose: 1,700 mg/kg/17 week- intermittent Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Gastrointestinal: Tumors

Skin and Appendages: Tumors
CNREA8 6,617,1946
subcutaneous
mouse
lowest published toxic dose: 400 mg/kg (15 day pregnant) Tumorigenic: Equivocal tumorigenic agent by RTECS criteria

Reproductive: Tumorigenic effects: Transplacental tumorigenesis

Liver: Tumors
IJCNAW 20,293,1977
subcutaneous
rat
lowest published toxic dose: 2,600 mg/kg/43 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Liver: Tumors
JJCREP 85,794,1994
skin
rat
lowest published toxic dose: 260 mg/kg/71 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Endocrine: Adrenal cortex tumors

Skin and Appendages: Tumors
JNCIAM 10,1201,1950
skin
rat
toxic dose : 2,590 mg/kg/23 week- intermittent Tumorigenic: Carcinogenic by RTECS criteria

Ear: Tumors

Liver: Tumors
CNREA8 28,234,1968


ACUTE TOXICITY DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
intraperitoneal
mouse
lethal dose (50 percent kill): 470 mg/kg N/R MUREAV 223,361,1989
intraperitoneal
rat
lowest published lethal dose: >200 mg/kg N/R ARTODN 56,151,1985
oral
mouse
lethal dose (50 percent kill): 810 mg/kg Peripheral Nerve and Sensation: Spastic paralysis with/without sensory change

Behavioral: Altered sleep time (including change in righting reflex)

Kidney, Ureter, and Bladder: Other changes in urine composition
PSEBAA 143,1117,1973
oral
rat
lowest published toxic dose: 150 mg/kg Liver: Changes in liver weight

Endocrine: Changes in thymus weight

Nutritional and Gross Metabolic: Weight loss or decreased weight gain
CTSRCS 288,371,1997
oral
rat
lowest published toxic dose: 345 mg/kg Skin and Appendages: Other: Breast

Tumorigenic: Tumor types after systemic administration not seen spontaneously
NATUAS 189,204,1961
oral
rat
lowest published toxic dose: 517.5 mg/kg Behavioral: General anesthetic NATUAS 189,204,1961


OTHER MULTIPLE DOSE DATA AND REFERENCES:

ROUTE/
ORGANISM
DOSE
EFFECT

REFERENCE
oral
rat
lowest published toxic dose: 564 mg/kg/3 week- continuous Liver: Fatty liver degeneration

Liver: Hepatitis, fibrous (cirrhosis, post- necrotic scarring)

Liver: Other changes
APJAAG 36,1039,1986
oral
rat
lowest published toxic dose: 336 mg/kg/16 week- continuous Nutritional and Gross Metabolic: Weight loss or decreased weight gain TOSCF2 55,44,2000
oral
rat
lowest published toxic dose: 42 mg/kg/2 week- continuous Liver: Other changes TOSCF2 55,44,2000
oral
rat
lowest published toxic dose: 672 mg/kg/16 week- continuous Tumorigenic: Cells (cultured) transformed TOSCF2 55,44,2000
oral
rat
lowest published toxic dose: 1,344 mg/kg/4 week- continuous Liver: Hepatitis (hepatocellular necrosis), zonal TOSCF2 55,44,2000
oral
rat
lowest published toxic dose: 40 mg/kg/5 day- intermittent Liver: Other changes TOXID9 72,360,2003


REVIEWS:

ORGANIZATION STANDARD
REFERENCE

TOXICOLOGY REVIEW
32XPAD -,49,1975
TOXICOLOGY REVIEW
85CVA2 5,63,1970
TOXICOLOGY REVIEW
ZEKBAI 71,32,1968
TOXICOLOGY REVIEW
ADCSAJ 13,271,1970
TOXICOLOGY REVIEW
BLFSBY 24,129,1983
TOXICOLOGY REVIEW
ARPTDI 43,485,2003


STANDARDS AND REGULATIONS:

ORGANIZATION STANDARD
REFERENCE

Mine Safety and Health Administration (MSHA) STANDARD air-SUSPECTED CARCINOGEN DTLWS* 3,8,1973
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (General Industry) see Code of Federal Regulations (CFR) 29,1910.1014 CFRGBR 29,1910.1000,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Construction) see Code of Federal Regulations (CFR) 29,1926.1114 CFRGBR 29,1926.55,1994
Occupational Safety and Health Administration (OSHA) Permissible Exposure Limit (Shipyards) see Code of Federal Regulations (CFR) 29,1915.1014 CFRGBR 29,1915.1000,1993
Occupational Safety and Health Administration (OSHA) cancer suspect agent CFRGBR 29,1910.1014,1987
Occupational Exposure Limit - BELGIUM Carcinogen, JAN1993
Occupational Exposure Limit - FINLAND Carcinogen, JAN1993
Occupational Exposure Limit - SWEDEN Carcinogen, JAN1999


NIOSH DOCUMENTATION AND SURVEILLANCE:

ORGANIZATION STANDARD or SURVEY
REFERENCE

National Institute for Occupational Safety and Health (NIOSH) Recommended Exposure Level TO 2-ACETYLAMINOFLUORENE-air Carcinogen use 29 Code of Federal Regulations (CFR) 1910.1014 NIOSH* DHHS #92-100,1992
National Occupational Exposure Survey 1983 National Occupational Exposure Survey 1983: Hazard Code: X6612;
Number of Industries 1;
Total Number of Facilities 75;
Number of Occupations 1;
Total Number of Employees Exposed 373


STATUS IN FEDERAL AGENCIES:

ORGANIZATION
REFERENCE

EPA GENETOX PROGRAM 1988, Positive: Body fluid assay; Carcinogenicity-mouse/rat
EPA GENETOX PROGRAM 1988, Positive: Host-mediated assay; L5178Y cells in vitro-TK test
EPA GENETOX PROGRAM 1988, Positive: Mammalian micronucleus; E coli polA with S9
EPA GENETOX PROGRAM 1988, Positive: Histidine reversion-Ames test; In vitro SCE-nonhuman
EPA GENETOX PROGRAM 1988, Positive: In vitro UDS in rat liver
EPA GENETOX PROGRAM 1988, Positive/dose response: Cell transform.-BALB/c-3T3; SHE-clonal assay
EPA GENETOX PROGRAM 1988, Negative: Cell transform.-SA7/SHE; E coli polA without S9
EPA GENETOX PROGRAM 1988, Negative: In vitro SCE-human lymphocytes; In vitro SCE-human
EPA GENETOX PROGRAM 1988, Negative: Sperm morphology-mouse; V79 cell culture-gene mutation
EPA GENETOX PROGRAM 1988, Negative: S cerevisiae gene conversion; S cerevisiae-homozygosis
EPA GENETOX PROGRAM 1988, Inconclusive: Cell transform.-RLV F344 rat embryo
EPA GENETOX PROGRAM 1988, Inconclusive: In vivo SCE-nonhuman; D melanogaster Sex-linked lethal
EPA GENETOX PROGRAM 1988, Inconclusive: In vitro UDS-human fibroblast
EPA GENETOX PROGRAM 1988, Positive: CHO gene mutation
EPA TSCA Section 8(b) CHEMICAL INVENTORY
Chemical produced but exact use not known
EPA TSCA Section 8(d) unpublished health/safety studies
EPA TSCA TEST SUBMISSION (TSCATS) DATA BASE, JANUARY 2001
NTP 10th Report on Carcinogens,2002:Reasonably anticipated to be a human carcinogen


REFERENCES:

CODEN
REFERENCE

32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975
85CVA2 "Oncology 1970, Proceedings of the Tenth International Cancer Congress," Chicago, Year Book Medical Pub., 1971
ADCSAJ Advances in Chemistry Series. (American Chemical Soc., Distribution Office Dept. 223, POB 57136, West End Stn., Washington, DC 20037) No.1- 1950-
AJCNAC American Journal of Clinical Nutrition. (American Soc. for Clinical Nutrition, Inc., 9650 Rockville Pike, Bethesda, MD 20814) V.2- 1954-
APJAAG Acta Pathologica Japonica. (Japan Publications Trading Co., Ltd., POB 5030, Tokyo International, Tokyo 101-31, Japan) V.1- 1951-
ARPAAQ Archives of Pathology. (Chicago, IL) V.5(3)-50(3), 1928-50; V.70-99, 1960-75. For publisher information, see APLMAS.
ARPTDI Annual Review of Pharmacology and Toxicology. (Annual Reviews, Inc., POB 10139, Palo Alto, CA 94303) V.16- 1976-
ARTODN Archives of Toxicology. (Springer-Verlag, Heidelberger Pl. 3, D-1000 Berlin 33, Fed. Rep. Ger.) V.32- 1974-
ATSUDG Archives of Toxicology, Supplement. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) No.1- 1978-
BANRDU Banbury Report. (Cold Spring Harbor Laboratory, POB 100, Cold Spring Harbor, NY 11724) V.1- 1979-
BBRCA9 Biochemical and Biophysical Research Communications. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947-
BLFSBY Basic Life Sciences. (Plenum Pub. Corp., 223 Spring St., New York, NY 10003) V.1- 1973-
CALEDQ Cancer Letters (Shannon, Ireland). (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1975-
CBINA8 Chemico-Biological Interactions. (Elsevier Scientific Pub. Ireland Ltd., POB 85, Limerick, Ireland) V.1- 1969-
CFRGBR Code of Federal Regulations. (U.S. Government Printing Office, Supt. of Documents, Washington, DC 20402)
CNJGA8 Canadian Journal of Genetics and Cytology. (National Research Council of Canada, Publication Sales and Distribution, Ottawa ON K1A OR6, Canada) V.1- 1959-
CNREA8 Cancer Research. (Public Ledger Building, Suit 816, 6th & Chestnut Sts., Philadelphia, PA 19106) V.1- 1941-
CPBTAL Chemical and Pharmaceutical Bulletin. (Japan Pub. Trading Co., USA, 1255 Howard St., San Francisco, CA 94103) V.6- 1958-
CRNGDP Carcinogenesis (London). (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1980-
CTSRCS Cell and Tissue Research. (Springer-Verlag New York, Inc., Service Center, 44 Hartz Way, Secaucus, NJ 07094) V.148- 1974-
DTLWS* "Documentation of the Threshold Limit Values for Substances in Workroom Air," Supplements. For publisher information, see 85INA8.
ECEBDI Experimental Cell Biology. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.44- 1976-
EJCAAH European Journal of Cancer (Elsevier Science, P.O.Box 7247-7682,Philadelphia,PA 19170 -7682,USA OR Elsevier Science B.V.,P.O.Box 1270,1000 BG Amsterdam,The Netherlands) V. 1- 1965-
EMMUEG Environmental and Molecular Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.10- 1987-
ENMUDM Environmental Mutagenesis. (New York, NY) V.1-9, 1979-87. For publisher information, see EMMUEG.
EXMPA6 Experimental and Molecular Pathology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1962-
FCTOD7 Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982-
GANNA2 Gann. Japanese Journal of Cancer Research. (Tokyo, Japan) V.1-75, 1907-84. For publisher information, see JJCREP.
GMCRDC Gann Monograph on Cancer Research. (Plenum Pub. Corp., 233 Spring St., New York, NY 10013) No. 11- 1971-
IARCCD IARC Scientific Publications. (Geneva, Switzerland) No.1-26, 1971-78. For publisher information, see IAPUDO.
IJCNAW International Journal of Cancer. (International Union Against Cancer, 3 rue du Conseil- General, 1205 Geneva, Switzerland) V.1- 1966-
INURAQ Investigative Urology. (Baltimore, MD) V.1-19, 1963-81. For publisher information, see JOURAA.
JCPCBR Journal of Clinical Pharmacology. (Hall Assoc., PO Box 482, Stamford, CT 06904) V.13- 1973-
JJCREP Japanese Journal of Cancer Research. (Elsevier Science Pub. BV, POB 211, 1000 AE Amsterdam, Netherlands) V.76- 1985-
JJIND8 JNCI, Journal of the National Cancer Institute. (Washington, DC) V.61-79, 1978-87. For publisher information, see JNCIEQ.
JNCIAM Journal of the National Cancer Institute. (Washington, DC) V.1-60, 1940-78. For publisher information, see JJIND8.
JTEHD6 Journal of Toxicology and Environmental Health. (Hemisphere Pub., 1025 Vermont Ave., NW, Washington, DC 20005) V.1- 1975/76-
KAIZAN Kaibogaku Zasshi. Journal of Anatomy. (Nippon Kaibo Gakkai, c/o Tokyo Daigaku Igakubu, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan) V.1- 1928-
KIKNAJ Kokuritsu Idengaku Kenkyusho Nenpo. Annual Report of the National Institute of Genetics. (Kokuritsu Idengaku Kenkyusho, 1111 Yata, Mishima, Shizuoka-ken 411, Japan) No. 1- 1949-
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964-
MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986-
NATUAS Nature. (Nature Subscription Dept., POB 1018, Manasguan, NJ 08736) V.1- 1869-
NIOSH* National Institute of Occupational Safety and Health, U.S. Dept. of Health, Education, and Welfare, Reports and Memoranda.
PAACA3 Proceedings of the American Association for Cancer Research. (Waverly Press, 428 E. Preston St., Baltimore, MD 21202) V.1- 1954-
PAMIAD Pathologica et Microbiologia. (Basel, Switzerland) V.23-43, 1960-75. For publisher information, see ECEBDI.
PMRSDJ Progress in Mutation Research. (Elsevier Science Pub. Co., Inc., 52 Vanderbilt Ave., New York, NY 10017) V.1- 1981-
PNASA6 Proceedings of the National Academy of Sciences of the United States of America. (National Academy of Sciences, Printing & Pub. Office, 2101 Constitution Ave., Washington, DC 20418) V.1- 1915-
PSEBAA Proceedings of the Society for Experimental Biology and Medicine. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1903/04-
SHKKAN Shika Kiso Igakkai Zasshi. Journal of the Japanese Association for Basic Dentistry. (Shika Kiso Igakkai, Hanayama Bldg., 1-44-2 Komagome, Toshima-ku, Tokyo 170, Japan) V.1- 1959-
SinJF# Personal Communication from J.F. Sina, Merck Institute for Therapeutic Research, West Point, PA 19486, Oct. 26, 1982
TCMUD8 Teratogenesis, Carcinogenesis, and Mutagenesis. (Alan R. Liss, Inc., 41 E. 11th St., New York, NY 10003) V.1- 1980-
TOSCF2 Toxicological Sciences (Oxford University Press, 6277 Sea Harbor Drive, Orlando, FL 32887 ) V. 41, Jan. 1998-
TOXID9 Toxicologist. (Soc. of Toxicology, Inc., 475 Wolf Ledge Parkway, Akron, OH 44311) V.1- 1981-
TXAPA9 Toxicology and Applied Pharmacology. (Academic Press, Inc., 1 E. First St., Duluth, MN 55802) V.1- 1959-
TXCYAC Toxicology. (Elsevier Scientific Pub. Ireland, Ltd., POB 85, Limerick, Ireland) V.1- 1973-
ZEKBAI Zeitschrift fuer Krebsforschung. (Berlin, Fed. Rep. Ger.) V.1-75, 1903-71. For publisher information, see JCROD7.

Chemical produced but exact use not known

RTECS Compound Description:
   Tumorigen
   Mutagen
   Reproductive Effector
   Human Data

Click Here for Additional Information about RTECS